title: Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab:  a case series.
abstract: OBJECTIVE
  In refractory pouchitis, infliximab (IFX) has been used as rescue therapy; however, there is no clinical evidence for the use of adalimumab (ADA). The aim of this study was to report the efficacy of ADA in patients with refractory pouchitis previously treated with IFX.
  
  
  METHODS
  A retrospective, open-label, case series was designed. Patients with chronic refractory pouchitis treated with ADA were included. All patients were previously treated with IFX. The short-term and mid-term efficacy of ADA was evaluated.
  
  
  RESULTS
  Eight patients with chronic refractory pouchitis treated with ADA were included. After 8 weeks, 13% of the patients achieved remission and 62% showed a clinical response. At week 26, 13% achieved remission and 38% showed a clinical response. At week 52, 50% of the patients avoided a permanent ileostomy but only 25 achieved remission.
  
  
  CONCLUSIONS
  ADA treatment was found to be an alternative for patients with chronic refractory pouchitis previously treated with IFX.
authors.affiliation: Department of Gastroenterology, University Hospital, Santiago de Compostela, Spain. manubarreiro@hotmail.com
authors.forename: Manuel
authors.initials: M
authors.lastname: Barreiro-de Acosta
authors.forename: Orlando
authors.initials: O
authors.lastname: García-Bosch
authors.forename: Jordi
authors.initials: J
authors.lastname: Gordillo
authors.forename: Miriam
authors.initials: M
authors.lastname: Mañosa
authors.forename: Luis
authors.initials: L
authors.lastname: Menchén
authors.forename: Raquel
authors.initials: R
authors.lastname: Souto
authors.forename: Ignacio
authors.initials: I
authors.lastname: Marin-Jimenez
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002908:Chronic Disease; D003093:Colitis, Ulcerative / Q000601:surgery; D004341:Drug Evaluation; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D019449:Pouchitis / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab